Turning Scientific Discoveries Into Treatments

TL;DR

NIH is making efforts to bridge the gap between basic discoveries in genomics and clinical benefits, focusing on prevention and better treatments for diseases.

Transcript

we are experiencing right now a remarkable Deluge of Discovery in terms of the causes of disease much of it coming out of genomics the ability to pinpoint at the molecular level what pathway has gone Ary in causing a particular medical condition and that in itself is exciting because it's new information but what you really want to do is to take th... Read More

Key Insights

• 👻 Genomics allows for a better understanding of diseases at the molecular level, paving the way for targeted therapies.
• 🥡 The private sector has historically driven therapeutic development, but NIH is now taking a more active role in advancing therapies.
• 🖤 NIH's focus includes prevention strategies and improved treatments for diseases that lack economic incentives.
• 💪 Building a stronger relationship between NIH and the FDA facilitates the development and oversight of therapeutic compounds.
• 🍳 The Blockbuster model for drug development is becoming less viable as diseases are broken down into subsets based on molecular understanding.
• 📽️ NIH aims to bring more effective treatments to the public by investing in academic projects and collaborating with the private sector.
• ❓ NIH has established clinical centers across the country to conduct initial clinical trials for potential therapeutics.

Questions & Answers

Q: What are some of the benefits of genomics in understanding and treating diseases?

Genomics allows us to pinpoint the molecular causes of diseases, providing new information for the development of preventive and therapeutic strategies.

Q: How has the private sector historically approached therapeutic development?

The private sector has traditionally relied on empirical methods to identify potential therapeutics, trying different compounds without always knowing why they work.

Q: What role does NIH play in bridging the gap between basic discoveries and clinical benefits?

NIH has become more involved in high-throughput screening and is investing in carefully chosen projects to support their progress towards therapeutic development.

Q: Why is the valley of death a critical challenge for drug development?

The valley of death refers to the point where a potential therapeutic moves from lab research to testing in animals and humans. It requires extensive and expensive processes, leading many projects to fail.

Summary & Key Takeaways

• Genomics has enabled the identification of molecular pathways causing medical conditions, leading to a Deluge of Discovery.

• The private sector has historically focused on developing therapies, often through empirical methods, but recent advancements allow for rational strategies.

• NIH is actively involved in the screening of chemical shapes to find compounds with the right properties and is investing in academic projects that lack economic incentives.